Ticker
ABOS

Price
5.62
Stock movement up
+0.01 (0.09%)
Company name
Acumen Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
229.80M
Ent value
78.87M
Price/Sales
-
Price/Book
1.17
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-14.01%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-09-08
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head-Investor RelationsDan O'Connell - Chief...
August 11, 2023

iO Charts is a Seeking Alpha partner

The following slide deck was published by Acumen Pharmaceuticals, Inc.
August 9, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABOS does not pay dividends or no data was received
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book1.17
EV to Sales-
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
August 8, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 19, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count40.93M
EPS (TTM)-0.95
FCF per share (TTM)-0.69

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-39.40M
Net income (TTM)-38.34M
EPS (TTM)-0.95
EPS (1y forward)-1.23

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash157.54M
Net receivables121.00K
Total current assets202.56M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets203.26M
Accounts payable2.08M
Short/Current long term debt133.00K
Total current liabilities6.61M
Total liabilities6.61M
Shareholder's equity196.65M
Net tangible assets196.65M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-27.59M
Capital expenditures (TTM)158.00K
Free cash flow (TTM)-27.75M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-19.50%
Return on Assets-18.86%
Return on Invested Capital-19.48%
Cash Return on Invested Capital-14.10%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open5.61
Daily high5.66
Daily low5.52
Daily Volume158K
All-time high20.28
1y analyst estimate15.83
Beta-
EPS (TTM)-0.95
Dividend per share-
Ex-div date-
Next earnings date13 Nov 2023

Downside potential

Loading...
Downside potential data
ABOSS&P500
Current price drop from All-time high-72.31%-6.74%
Highest price drop-84.81%-56.47%
Date of highest drop11 May 20229 Mar 2009
Avg drop from high-63.73%-11.49%
Avg time to new high551 days13 days
Max time to new high550 days1805 days
Acumen reported positive topline results from its phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early Alzheimer's Disease. Read more here.
July 18, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 17, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABOS (Acumen Pharmaceuticals Inc) company logo
Marketcap
229.80M
Marketcap category
Small-cap
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Employees
14
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 17, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 17, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual AAIC. Check out our recommendation on ABOS stock.
July 13, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
July 9, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
June 13, 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head IRDaniel O'Connell - President and CEOEric...
May 14, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
May 9, 2023
The following slide deck was published by Acumen Pharmaceuticals, Inc.
March 27, 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head IRDaniel O'Connell - President and Chief...
March 27, 2023
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
March 27, 2023
Acumen Pharmaceuticals is an early-stage developmental concern focusing on development treatments for Alzheimer's. Click here to read ABOS' investment analysis.
December 26, 2022
Acumen Pharmaceuticals (ABOS) Q3 2022 Earnings Conference Call Nov 14, 2022 04:30 PM ET
November 15, 2022
iO Charts is a Seeking Alpha partnerNext page